Clinical Trial Search

Primary: Semen to Plasma Ratio of HIV Concentration During the Dosing Interval for Dar, Evr, Mar & Ral. — 0.20; 0.16; 0.92; 4.32 Inhibitory concentration ratio

Primary: Seminal Concentrations of Raltegravir. — 0.18; 1.91 mg/l

Primary: Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells — 0.58 Log-10 copies/10^6…

Primary: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic…

Primary: Semen Clearance (CL) of Tenofovir — 33.88; 51.21; 5.65 L/hr

Primary: Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline — 4.854; 4.861; 4.840 log10 copies/milliliter(log10 copies/mL)

Primary: CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) — 1.01 ratio

Primary: Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline — 4.873; 4.840; 4.886 log10 copies/milliliter(log10 copies/mL)

Primary: Change From Baseline in Human Immunodeficiency Virus (HIV-1) Viral Load (Ribonucleic Acid [RNA]) — -0.890; -1.194; -0.953; -0.604 log10 copies/mL

Primary: The Change in Hepatitis C Viral Load From Baseline to 4 Weeks of Maraviroc or No Maraviroc — 2035071; 2027648; 2082302; 1216383 International Units/ml — p=0.13

Primary: Change in CD4+ T-cell Count — 12 cells/mm^3 — p=0.97

Primary: Concentration of Doravirine in Seminal Plasma Fluid — 127 ng/ml

Primary: Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Dose-Finding — 0; 0; 0; 0 percentage of participants

Primary: Tissue Raltegravir Concentrations — 117 ng/mL

Primary: Mean Glomerular Filtration Rate by Iohexol Clearance at Week 52 — 37.0; 40.1 mL/min/1.73 m²

Primary: Cmin/Cmax: Steady-state Plasma Amprenavir (APV) Pharmacokinetics ( PK) Following Admin of Fosamprenavir (FPV) 1400mg BID, FPV 700mg/Ritonavir (RTV) 100 mg BID, or FPV…

Primary: Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C AIDS -Defining Opportunistic Infections — 22.28; 41.77…

Primary: Standing and Supine Systolic and Diastolic Blood Pressure (BP) — 118.36; 119.47; 68.06; 69.99 mm Hg

Primary: The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day — 0.99 ratio

Primary: Rate of Completion — 7 Participants

Primary: Change in the Density of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Following Antiretroviral Therapy Regimen — 24; 89; 119; 566…

Primary: Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast) — 7356.3; 9502.1; 6496.0; 1320.7 ng*hr/mL

Primary: Percent Change in FMD — 0.57; -0.05 percent change in FMD — p=0.17

Primary: Peak Plasma Concentration of Etravirine in Plasma — 497.6 ng/ml

Primary: Week 24 Change in Percentage of CD8+ T Cells That Co-express CD38 and HLA DR (Week 24 %CD38+HLA-DR+ CD8+ T Cells Minus Baseline %CD38+HLA-DR+ CD8+ T Cells) — 2.2; -0.7…

Primary: Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs) — 40; 9; 34 Participants

Primary: Percentage of Participants With Plasma HIV-1 RNA >50 — 12.5 percentage of participants

Primary: Pharmacokinetics of Maraviroc and Rifabutin AUC 0-12/24 — 1026.2; 847.0; 4221.9; 331.9 h*μg/L

Primary: Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE) — 13.2; 2.4; 6.3; 1.6 percentage of participants

Primary: ZDV-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject — 33.89; 29.7 pmol/10^6 cells